Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Current Deferred Revenue (2019 - 2025)

Historic Current Deferred Revenue for 4D Molecular Therapeutics (FDMT) over the last 7 years, with Q3 2025 value amounting to $360000.0.

  • 4D Molecular Therapeutics' Current Deferred Revenue fell 7262.36% to $360000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $360000.0, marking a year-over-year decrease of 7262.36%. This contributed to the annual value of $257000.0 for FY2024, which is 586.08% down from last year.
  • 4D Molecular Therapeutics' Current Deferred Revenue amounted to $360000.0 in Q3 2025, which was down 7262.36% from $1.1 million recorded in Q2 2025.
  • Over the past 5 years, 4D Molecular Therapeutics' Current Deferred Revenue peaked at $18.8 million during Q1 2021, and registered a low of $257000.0 during Q4 2024.
  • Moreover, its 5-year median value for Current Deferred Revenue was $1.4 million (2023), whereas its average is $3.0 million.
  • In the last 5 years, 4D Molecular Therapeutics' Current Deferred Revenue plummeted by 8607.14% in 2023 and then soared by 725.94% in 2024.
  • 4D Molecular Therapeutics' Current Deferred Revenue (Quarter) stood at $5.1 million in 2021, then plummeted by 61.49% to $2.0 million in 2022, then tumbled by 86.07% to $273000.0 in 2023, then dropped by 5.86% to $257000.0 in 2024, then skyrocketed by 40.08% to $360000.0 in 2025.
  • Its Current Deferred Revenue stands at $360000.0 for Q3 2025, versus $1.1 million for Q2 2025 and $866000.0 for Q1 2025.